The history of Sildenafil presents a complex case for observers in the medicinal sector. While initially a phenomenal success, creating billions, the intellectual property end and the subsequent flood of off-brand alternatives have considerably impacted income. This poses questions about the ongoing sustainability of similar therapeutic development